Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Slides:

Advertisements

Similar presentations

Figure 1 The heterogenous landscape of triple-negative breast cancer

Advertisements

Reproduced with permission from Cronin M et al

Figure 1 Estimated annual percentages of new

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 1 Cellular processes involved in cancer development

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 2 Signalling pathways and physiological domains that are

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 A schematic representation of the role

Figure 1 Balance between proteasomal load and capacity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 2 Metabolic heterogeneity in tumours

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 3 The yin and yang of tumour-associated

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Effects of imatinib on components of the anticancer immunosurveillance system Figure 2 | Effects of imatinib on components of the anticancer immunosurveillance.

Figure 5 Palliative-care-referral patterns

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 2 Effect of chromosomal instability tolerance

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 2 Signalling downstream of the IL-6 receptor

The impact of FIH-1 on ASPP2 protein interactions.

Figure 1 Gene-expression quantification methods

Figure 2 Mechanisms of RET activation in cancer

Presentation transcript:

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer6. Nutritional factors can influence cancer development by affecting fundamental cellular processes, including those that regulate the balance between cell proliferation and death, appropriate cell differentiation, the expression of oncogenes and tumour-suppressor genes, cell signalling, and other factors in the cellular environment (such as hormonal factors) that influence gene expression. Thus, bioactive food components can interact with gene expression at multiple points, and furthermore, a specific food typically contains numerous components that interact additively or even synergistically with these cellular processes. Permission obtained from World Cancer Research Fund International © World Cancer Research Fund/American Institute for Cancer Research Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective (AICR, Washington District of Columbia, USA, 2007). Permission obtained from World Cancer Research Fund International © World Cancer Research Fund/American Institute for Cancer Research Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective (AICR, Washington District of Columbia, USA, 2007) Mayne, S. T. et al. (2006) Diet, nutrition, and cancer: past, present and future Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.24